Our experience of using oral anticoagulant Rivaroxaban in patients after cementless hip joint arthroplasty

Authors

DOI:

https://doi.org/10.15674/0030-598720103100-104

Keywords:

hip joint, arthroplasty, anticoagulant therapy, Rivaroxaban

Abstract

This article represents the first stage of a research in using a direct oral inhibitor of Xa factor, Rivaroxaban, in patients after cementless hip joint arthroplasty. The purpose of the present research was to study the efficacy and safety of the above drug preparation. The investigation involved 20 patients. The efficacy of this anticoagulant therapy was analysed; its assessment did not reveal either any manifestations of thrombotic complications (thrombosis of deep veins on the lower extremities, pulmonary thromboembolism) or cases of haemorrhagic complications. The safety was assessed by the results of general clinical and biochemical blood tests. This research demonstrated that taking of Rivaroxaban ensured high efficacy of anticoagulant therapy for preventing thromboembolic complications and preserved safety  for patients after hip joint arthroplasty.

References

  1. Вырва О. Е. Сравнение эффективности длительной терапии ривароксабаном и кратковременной эноксапарином для профилактики венозной тромбоэмболии после эндопротезирования тазобедренного сустава. Результаты исследований RECORD 2 [Текст] / О. Е. Вырва // Ортопед. травматол. — 2010. — № 1. — С. 110–114.
  2. Вырва О. Е. Сравнительная оценка эффективности ривароксабана и эноксапарина в профилактике тромбообразования после эндопротезирования тазобедренного сустава. Результаты исследований RECORD 1 [Текст] / О. Е. Вырва // Ортопед. травматол. — 2009. — № 3. — C. 97–100.
  3. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians — are they appropriate for orthopaedic surgery? [Text] / J. J. Callaghan, L. D. Dorr, G. A. Engh et al. // J. Arthroplasty. — 2005. — Vol. 20. — P. 273–274.
  4. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD 1 trial [Text] / B. Eriksson, L. Borris, R. Friedman et al. // Blood. — 2007. — Vol. 110. — Аbstract 6.
  5. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty [Text] / B. Eriksson, L. Borris, R. Friedman et al. // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2765–2775.
  6. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) for the American College of Chest Physicians [Text] / W. H. Geerts, D. Bergqvist, G. F. Pine et al. // Chest. — 2008. — Vol. 133. — P. 381–453.
  7. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial [Text] / A. K. Kakkar, B. Brenner, O. E. Dahl et al. // Lancet. — 2008. — Vol. 372. — P. 29–37.
  8. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study [Text] / P. Prandoni, O. Bruchi, P. Sabbion et al. // Arch Intern Med. — 2002. — Vol. 162. — P. 1966–1971.

Downloads

How to Cite

Filipenko, V., Vyrva, O., Kuznetsova, N., Malyk, R., & Pidgaiska, O. (2010). Our experience of using oral anticoagulant Rivaroxaban in patients after cementless hip joint arthroplasty. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (3), 100–104. https://doi.org/10.15674/0030-598720103100-104

Issue

No. 3 (2010)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2014 Volodymyr Filipenko, Oleg Vyrva, Nataliya Kuznetsova, Roman Malyk, Olga Podgayskaya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).